Trial Profile
PRISM-EXT: An Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota (CP101) in Subjects With Recurrence of Clostridium Difficile Infection
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 21 Dec 2022
Price :
$35
*
At a glance
- Drugs CP 101 Finch Therapeutics Group (Primary)
- Indications Clostridium difficile infections
- Focus Adverse reactions; Therapeutic Use
- Acronyms PRISM-EXT
- Sponsors Finch Research & Development
- 26 Oct 2022 Results assessing the safety and efficacy of CP101 for the Prevention of Recurrent C. difficile Infection presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2022
- 24 Oct 2022 According to a Finch Therapeutics Group media release, biomarker data from this study were presented at the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting.
- 24 Oct 2022 Results presented in a Finch Therapeutics Group media release.